That’s Jeff Brown’s take on best-in-breed biotech stocks in 2020.
We’ve already seen biotech deliver the biggest breakthrough since antibiotics – CRISPR gene editing.
It allows doctors to “cut” out faulty segments and “paste” new, healthy segments in your DNA. It’s effectively cured two blood diseases. And it’s now helping doctors make revolutionary cancer treatments.
Last year alone, the average gain for the top-performing stocks in the Nasdaq Biotech Index was 691%.
The top performer was Axsome Therapeutics (AXSM). It makes genetic therapies for depression and Alzheimer’s disease.
Last year, its shares shot up 3,565%.
And as you’ll see in today’s dispatch, Jeff believes these crypto-like gains are only getting started.
As we showed you last week, this is one to print out and pin beside your computer.
Because innovations in biotech – like all other tech – grow at an exponential rate.
The beauty of technology is it compounds over time. Better tech builds better tech… and so on. Until, suddenly, sci-fi tech is a reality.
As an investor, there’s no better place to be than right at the start of the sharp “elbow” pattern on the chart below.
And biotech has only started to hit the sharp elbow of its exponential growth phase.
In October 2016, he recommended Swiss-based CRISPR gene-editing company CRISPR Therapeutics (CRSP) to our Near Future Report readers.
When he issued his sell alert last month, CRSP was up 332%.
And in December 2019, Jeff closed a two-month trade at Early Stage Trader for a 432% win.
Early Stage Trader is the advisory he launched last year to help readers profit from developmental-stage tech and biotech firms ahead of catalysts that propel their stock prices higher.
That’s exactly what Jeff did with another biotech play, Synthorx (THOR).
He added the tiny cancer-fighting biotech firm to the Early Stage Trader model portfolio in October 2019 at $12.72 a share. In December 2019, he sent out a sell alert to his readers when the stock hit $67.71.
It’s our mission at The Daily Cut to identify major profit trends early on so you can grow your wealth.
And the good news is the rally in best-of-breed biotech stocks is just getting started.
It’s down to breakneck advances in gene editing. CRISPR is the most accurate… and easiest… way to deliver genetic “edits” to patients.
As I mentioned up top, this has already allowed doctors to effectively cure patients with two rare blood diseases – sickle cell disease and beta thalassemia.
But the successful treatment of these blood diseases is just the start. As CRISPR technology continues to advance at an exponential rate, Jeff says we’re on track to cure all 6,000 inherited diseases.
CRISPR firms are also working on curing cystic fibrosis… type 1 diabetes… and muscular dystrophy.
This is exponential growth in action. These new therapies weren’t in reach before. Now, all of a sudden, they’re here. Jeff…
If you’d asked me 20 years ago about whether I was excited about biotech, my answer would have been different. But today, we’re entering a renaissance in biotech, genetic editing, and therapeutic development. This is a central theme in all my research and one you can profit from for years to come.
Before coming on board at Legacy, he was a high-tech exec for nearly 30 years in Silicon Valley and Japan.
He’s also personally funded 130 private early-stage tech deals. And 93% of these deals have made him money.
Jeff is researching tech… and figuring out how to profit from it… morning to night.
I met with him last week on my trip to Legacy HQ in Delray Beach, Florida. He was rushing from a power lunch with two analysts… to record his upcoming training event.
Later, I saw him sitting at a makeshift desk… typing up a new research report to his subscribers.
Jeff has nailed calls on 5G… self-driving cars… and artificial intelligence (AI). But the biggest gains Jeff has delivered to his readers are in early-stage biotech firms.
The California-based company is combatting cancer by modifying DNA and then using it to boost sufferers’ immune response.
I won’t get into the weeds on how it works here. All you need to know is that the therapy is so promising… pharmaceutical giant Sanofi (SNY) swooped in two months after Jeff recommended it.
It bought Synthorx for $2.5 billion to boost its own cancer-drug pipeline.
Sanofi paid $68 a share. That was a 172% premium over the previous day’s closing price. And it’s 435% more than the price shares were trading at when Jeff recommended them to our paid-up Early Stage Trader subscribers.
Early Stage Trader is designed to help folks scoop up outsized gains in the stock market.
Jeff does this by recommending early-stage investments in tiny tech companies with massive potential.
And if you’ve followed Jeff’s advice, you know how fast-moving these stocks can be. There aren’t many things more exhilarating than waking up and realizing that you’ve just quintupled your money.
Keep in mind… Jeff recommended buying Synthorx on October 29. Sanofi swooped in to buy on December 9. That’s a holding time of just 41 days.
What’s so exciting about biotech in 2020 is that the exponential innovation… and profits… are only getting started. Jeff again…
Pay close attention to biotech this year. We’re at the beginning of a multiyear bull market in best-in-breed biotech stocks.
Think about it… We have an incredible genetic-editing technology called CRISPR. And we’re able to combine it with new diagnostic technologies and advances in computer processing power, artificial intelligence, and machine learning. This is going to drive exponential innovation in the underlying technology… and therefore investment.
We saw record levels of private investments in the biotechnology sector in 2019. And there’s no wonder. There’s almost nowhere else in the stock market where you have this pace of growth and innovation.
And once Wall Street sees this, what’s it going to do?
It will pour more cash into the sector.
As Jeff put it, “This is going to be like dumping fuel on a fire.”
If Jeff is right, they’re going to be a great focus for speculators this year.
One of his favorite biotech stocks right now is Vertex Pharmaceuticals (VRTX).
It’s already up nearly 50% in the model portfolio at his large-cap tech advisory, The Near Future Report. Along with CRISPR Therapeutics, it was behind the successful treatment of the two patients with blood diseases.
And Vertex is a company that Jeff expects will continue to deliver. Vertex has developed therapies that now treat 90% of the cystic fibrosis (CF) population.
CF is a fatal disease that affects more than 70,000 people worldwide. It causes digestive problems and a buildup of mucus in the lungs. Sufferers often die from lung diseases that set in as a result.
And Vertex has more CF therapies undergoing clinical trials… as well as therapies targeting muscular dystrophy… kidney diseases… and lung diseases in the pipeline.
Just remember to treat this as a speculation. Biotech stocks are highly volatile. So you never want to risk money that you can’t afford to lose.
It kicks off at 8 p.m. ET.
And it’s all about the strategy he’s been working on for the past five years.
It tells you when a major catalyst is about to shoot what he calls “timed stocks” higher.
This timer silently ticks down. And the exact moment it hits zero, these stocks can shoot higher.
I know it sounds unusual. But Jeff will reveal dozens of “timed stocks” during tomorrow’s training.
He’s found 119 “timed stocks” in the past few years. All of them – 100% – went up starting the moment their timer hit zero.
And the peak gain was enough to turn $5,000 into $1.3 million. So make sure to secure your spot for Jeff’s event here right now.
Regards,
Chris Lowe
January 21, 2020
Cartagena, Colombia
Like what you’re reading? Send your thoughts to feedback@legacyresearch.com.